Latest News

New hematologic, cardiovascular system link may have therapeutic implications


 

EXPERT ANALYSIS FROM ASH 2017

“If we understand that, we may be in a position to stratify these women based on thrombosis risk in the setting of estrogen exposure. I think the other thing that will come out of the work, as we begin to understand the mechanisms for this relationship, is the identification of targets that we could therapeutically modulate to reduce this risk,” he added.

Eventually, as more is learned about the mechanisms that underlie the relationship between OPA1 and platelet activation, the findings might also lead to new approaches for reducing the risk of thrombosis in men, he noted.

Dr. Abel and Dr. Weyrich reported having no relevant financial disclosures.

Pages

Recommended Reading

Targeting PCSK9 inhibitors to reap most benefit
MDedge Internal Medicine
VIDEO: U.S. hypertension guidelines reset threshold to 130/80 mm Hg
MDedge Internal Medicine
Keep PCI patients on aspirin for noncardiac surgery
MDedge Internal Medicine
Prescribers mostly ignore clopidogrel pharmacogenomic profiling
MDedge Internal Medicine
Pharmacomechanical thrombolysis does not reduce post-thrombotic syndrome risk
MDedge Internal Medicine
Acute kidney injury linked with doubled inpatient VTEs
MDedge Internal Medicine
Poststroke depression raises risk of cerebrovascular death 35-fold
MDedge Internal Medicine
VIDEO: Anticoagulant underprescribing common, jeopardizing atrial fib patients
MDedge Internal Medicine
Thrombosis risk is elevated with myeloproliferative neoplasms
MDedge Internal Medicine
Surgical LAA occlusion tops anticoagulation for AF thromboprotection
MDedge Internal Medicine

Related Articles